Genevieve Ubeaud-Sequier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Genevieve Ubeaud-Sequier has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Bénédicte Gourieux
Service de Pharmacie-Stérilisation, Laboratoire de contrôle, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, 67098 Strasbourg, France
2 shared publicationsLaurent Perello
Service de Pharmacie-Stérilisation, Laboratoire de contrôle, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, 67098 Strasbourg, France
2 shared publications- Anne Gairard-Dory
Service pharmacie stérilisation, hôpitaux universitaires de Strasbourg, 1, place de l’Hôpital, 67000 Strasbourg, France
1 shared publication Anne-Cécile Gairard Dory
Department of Pharmacy, University Hospital Strasbourg, Strasbourg, France
1 shared publicationChristian D. Muller
UMR CNRS 7200, Laboratoire d'Innovation Thérapeutique, Université de Strasbourg, FMTS, Faculté de Pharmacie, Illkirch, France
1 shared publicationCoralie Boulanger
Service de Pharmacie-Stérilisation, Laboratoire de contrôle, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, 67098 Strasbourg, France
1 shared publication
Latest Publications
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 499 (1-2) , 343-350
A UV-Raman spectrometry method for quality control of anticancer preparations: Results after 18 months of implementation in hospital pharmacy
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 499 (1-2) , 343-350
A UV-Raman spectrometry method for quality control of anticancer preparations: Results after 18 months of implementation in hospital pharmacy
- Open Access
- 11 February 2013
- Published by Wiley in Cytometry Part A
- Vol. 83A (4) , 403-408
Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry
- 11 February 2013
- Published by Wiley in Cytometry Part A
- Vol. 83A (4) , 403-408
Open AccessImplication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry
- 14 July 2012
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 20 (1) , 46-49
Stability of an oral ranitidine suspension (15 mg/ml)
Purpose The aim of this study was to evaluate the microbiological and physicochemical stability of 15 mg/ml ranitidine hydrochloride suspension. Methods 15 mg/ml ranitidine hydrochloride suspensions were prepared in commercial vehicle (ORA-BLEND). Suspensions were kept for 90 days at 4 °C and 25 °C. The microbiological stability was assessed by microbial enumeration tests and specific search for Escherichia coli The physical stability was assessed by colour change, pH and chromatogram peaks. Ranitidine was assayed using high-performance liquid chromatography. Each series of three batches at each storage condition was combined into one representative exponential curve for the evolution of degradation of ranitidine suspension. Stability was defined as a remaining concentration of at least 95 % of the initial concentration (ie, 5% degradation). Results Culture of the different suspension samples resulted in no bacterial or fungal growth. Specific search for E coli was negative. There was colour change for each batch. No change from the initial pH (4·2) occurred in samples stored at 4°C but, for samples stored at 25°C, the pH increased from 4·2 to 4·9. Unidentified peaks corresponding to degradation products appeared on the chromatogram at day 30 for suspensions stored at 25°C and at day 60 for suspensions stored at 4°C. Conclusions Ranitidine hydrochloride suspension in amber glass was stable for up to 27 days when stored at 4°C and up to 5 days at 25°C. It is recommended that nurses should allow ranitidine suspension to reach room temperature before use and administration to patients.
- 14 July 2012
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 20 (1) , 46-49
Stability of an oral ranitidine suspension (15 mg/ml)
Purpose The aim of this study was to evaluate the microbiological and physicochemical stability of 15 mg/ml ranitidine hydrochloride suspension. Methods 15 mg/ml ranitidine hydrochloride suspensions were prepared in commercial vehicle (ORA-BLEND). Suspensions were kept for 90 days at 4 °C and 25 °C. The microbiological stability was assessed by microbial enumeration tests and specific search for Escherichia coli The physical stability was assessed by colour change, pH and chromatogram peaks. Ranitidine was assayed using high-performance liquid chromatography. Each series of three batches at each storage condition was combined into one representative exponential curve for the evolution of degradation of ranitidine suspension. Stability was defined as a remaining concentration of at least 95 % of the initial concentration (ie, 5% degradation). Results Culture of the different suspension samples resulted in no bacterial or fungal growth. Specific search for E coli was negative. There was colour change for each batch. No change from the initial pH (4·2) occurred in samples stored at 4°C but, for samples stored at 25°C, the pH increased from 4·2 to 4·9. Unidentified peaks corresponding to degradation products appeared on the chromatogram at day 30 for suspensions stored at 25°C and at day 60 for suspensions stored at 4°C. Conclusions Ranitidine hydrochloride suspension in amber glass was stable for up to 27 days when stored at 4°C and up to 5 days at 25°C. It is recommended that nurses should allow ranitidine suspension to reach room temperature before use and administration to patients.